|
Volumn 125, Issue 1, 2005, Pages 37-48
|
Raloxifene hydrochloride (Evista® Tablet 60 mg) for postmenopausal osteoporosis: Mode of action and clinical efficacy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALKALINE PHOSPHATASE;
AMINO TERMINAL TELOPEPTIDE;
FULVESTRANT;
LUCIFERASE;
N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE;
NEW DRUG;
OSTEOCALCIN;
PLACEBO;
RALOXIFENE;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
TRANSFORMING GROWTH FACTOR BETA3;
ANIMAL CELL;
ANIMAL EXPERIMENT;
BONE DENSITY;
BONE MINERAL;
BREAST CANCER;
CELL STRAIN MCF 7;
COMPUTER ASSISTED TOMOGRAPHY;
CONTROLLED STUDY;
DAILY LIFE ACTIVITY;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG STRUCTURE;
FEMALE;
HORMONE SUBSTITUTION;
HUMAN;
HUMAN CELL;
NONHUMAN;
OSTEOPOROSIS;
OVARIECTOMY;
POSTMENOPAUSE;
POSTMENOPAUSE OSTEOPOROSIS;
QUALITY OF LIFE;
REVIEW;
TABLET FORMULATION;
TREATMENT OUTCOME;
VERTEBRA FRACTURE;
ANIMALS;
BONE AND BONES;
BONE DENSITY;
BONE REMODELING;
BONE RESORPTION;
BREAST NEOPLASMS;
CEREBROVASCULAR ACCIDENT;
CONTROLLED CLINICAL TRIALS;
CORONARY DISEASE;
FEMALE;
FRACTURES, BONE;
HUMANS;
OSTEOPOROSIS, POSTMENOPAUSAL;
RALOXIFENE;
RECEPTORS, ESTROGEN;
SELECTIVE ESTROGEN RECEPTOR MODULATORS;
TRANSCRIPTION FACTORS;
|
EID: 12444277292
PISSN: 00155691
EISSN: None
Source Type: Journal
DOI: 10.1254/fpj.125.37 Document Type: Review |
Times cited : (2)
|
References (45)
|